ABSTRACT The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)
Expert Panel identified and reviewed the available evidence for the ten most important areas …

Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Significant progress has been made in the understanding of the underlying cancer biology
of castration‐resistant prostate cancer (CRPC) with the androgen receptor (AR) signalling …

Background Enzalutamide and abiraterone acetate plus prednisone, which target the
androgen receptor axis, have expanded the treatment of advanced prostate cancer …

Several mechanisms facilitate the progression of hormone-sensitive prostate cancer to
castration-resistant prostate cancer (CRPC). At present, the approved chemotherapies for …

Simple Summary The past decade has seen the development and regulatory approval of a
large number of new treatment options for advanced prostate cancer. Despite this, the two …

Oral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated
for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries …

Aims Despite impressive survival benefits from new agents to treat metastasized prostate
cancer (PCa), progressive drug resistance hinders long-term response and restricts the …

The androgen receptor drives the growth of metastatic castration-resistant prostate cancer.
This has led to the development of multiple novel drugs targeting this hormone-regulated …